Key result
The authors highlight a 4.5% absolute risk reduction in the first week with DAPT versus aspirin and request a time-course analysis by intracranial arterial stenosis status in the CHANCE trial.
Why the study?
Does dual antiplatelet therapy reduce recurrent ischemic stroke compared to aspirin alone in patients with minor stroke or TIA and intracranial arterial stenosis?
Does dual antiplatelet therapy reduce recurrent ischemic stroke compared to aspirin alone in patients with minor stroke or TIA and intracranial arterial stenosis?
Answers are grounded in this paper and cite their sources.
This letter requests a detailed time-course analysis of ischemic stroke and hemorrhage risks by ICAS status in the CHANCE trial to better understand the early benefits of DAPT.
We read with interest the article by Pan et al.,1 which reported that the use of dual antiplatelet therapy (DAPT) showed an early benefit, compared to aspirin alone, for secondary ischemic stroke prevention after a minor stroke or TIA. The absolute risk reduction in the first week after the indexed event was 4.5%.1 The authors previously reported a nonsignificant absolute risk reduction in recurrent ischemic stroke of 2.3% with DAPT compared to aspirin alone in Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) participants with intracranial arterial stenosis (ICAS) over the 90-day follow-up period.2 In figure 1 from the article by Pan et al.,1 the benefit of DAPT compared with aspirin alone appears greater in the first 2 weeks among those with ICAS, with parallel risk curves thereafter. In this context, it would be valuable if the authors reported the time-course analysis for the risk of ischemic stroke and hemorrhage in the first, second, and third week by ICAS status. These data could help formulate possible mechanism-based interventions for acute stroke, which could then be tested in trials.
No takes yet. Share an insight, caveat, or question.
Gutiérrez et al. (2017) conducted a letter in minor stroke or TIA. dual antiplatelet therapy (DAPT) vs. aspirin alone was evaluated on recurrent ischemic stroke (ARR 4.5%). The authors highlight a 4.5% absolute risk reduction in the first week with DAPT versus aspirin and request a time-course analysis by intracranial arterial stenosis status in the CHANCE trial.
Synapse has enriched 10 related papers. Consider them for comparative context: